Certara and Merck expand collaboration to aid in data standards management.
PorAinvest
martes, 8 de julio de 2025, 8:06 am ET1 min de lectura
CERT--
The Pinnacle 21 platform is designed to address the increasing complexity of data standardization in modern digital trials. Phase III clinical trials now average 3.6 million datapoints, a threefold increase over the last decade [1]. The platform is designed to optimize clinical data flows for speed and quality, addressing these challenges at scale.
William F. Feehery, Chief Executive Officer of Certara, stated, "We are pleased to strengthen our ongoing collaboration with Merck to assist with data standards management and to expand the value of the Pinnacle 21 platform. Merck is a premier research-intensive company, and our teams are well-aligned in the goal of delivering high-quality research data faster to help save and improve lives around the world."
Certara's Pinnacle 21 Enterprise clinical data management and automation suite is used by over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. This latest collaboration with Merck underscores the platform's effectiveness in streamlining data management and regulatory compliance.
To learn more about Pinnacle 21 Enterprise clinical data management and automation suite, visit www.certara.com/pinnacle-21-enterprise-software/.
References:
[1] https://www.marketscreener.com/quote/stock/CERTARA-INC-116233106/news/Certara-Announces-Expansion-of-Clinical-Technology-Collaboration-with-Merck-50457014/
MRK--
Certara has announced a new collaboration with Merck to expand Merck's use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement builds on their existing technology collaboration to aid in regulatory submissions. The Pinnacle 21 platform is designed to solve data standardization challenges in modern digital trials at scale.
Certara, Inc. (Nasdaq: CERT) has announced a significant expansion in its collaboration with Merck, known as MSD outside the United States and Canada. The new agreement sees Merck's use of the Certara Pinnacle 21® (P21) enterprise software platform extended to include a metadata repository and data standards workflow management. This expansion builds upon Merck’s existing technology collaboration with Certara, aimed at aiding in regulatory submissions.The Pinnacle 21 platform is designed to address the increasing complexity of data standardization in modern digital trials. Phase III clinical trials now average 3.6 million datapoints, a threefold increase over the last decade [1]. The platform is designed to optimize clinical data flows for speed and quality, addressing these challenges at scale.
William F. Feehery, Chief Executive Officer of Certara, stated, "We are pleased to strengthen our ongoing collaboration with Merck to assist with data standards management and to expand the value of the Pinnacle 21 platform. Merck is a premier research-intensive company, and our teams are well-aligned in the goal of delivering high-quality research data faster to help save and improve lives around the world."
Certara's Pinnacle 21 Enterprise clinical data management and automation suite is used by over 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. This latest collaboration with Merck underscores the platform's effectiveness in streamlining data management and regulatory compliance.
To learn more about Pinnacle 21 Enterprise clinical data management and automation suite, visit www.certara.com/pinnacle-21-enterprise-software/.
References:
[1] https://www.marketscreener.com/quote/stock/CERTARA-INC-116233106/news/Certara-Announces-Expansion-of-Clinical-Technology-Collaboration-with-Merck-50457014/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios